Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Alzheimerâ€™s disease
- Parkinsons Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6572
IPSCIO Record ID: 28176
IPSCIO Record ID: 4400
(i) in vitro therapeutic test system that uses cultured human fibroblasts or any other method to detect and measure PKC and/or other assays with peripheral cells to predict the presence of Alzheimerâ€™s Disease in humans, and all succeeding test formats (including test kits);
(ii) the PKC activators (including bryostatin, analogs, PUFAs, and other PKC activators) and their therapeutic applications in humans or animals;
(iii) the LDL or ApoE-based drug delivery system that is targeted to enhance access of all manner of drugs and therapeutics to the brain by facilitation of transport of such drugs across the Blood-Brain-Barrier in humans or animals; and
(iv) the carbonic anhydrase activators and their therapeutic applications in humans or animals
Effective August 28, 2013, licensee signed a statement of work (SOW) with licensor pursuant to the License Agreement, whereby the Company has contracted for the further development of its AD diagnostic product. The project is intended to validate each of three biomarkers in a heterogeneous patient population to determine sensitivity and selectivity parameters for each biomarker, or combination of biomarkers, to detect Alzheimerâ€™s Disease. The three biomarkers to be evaluated are the PKCe levels, the Erk1/2 ratios, and the fibroblast morphology test.
IPSCIO Record ID: 223107
The term Patent Rights shall mean United States Patent Application Serial No. TBA, entitled 'Biomarkers for Neurodegenerative Disease,' filed TBA, which was developed by the Inventors, the inventions described and claimed therein, and all other pending United States patent applications or parts thereof and any United States patent which issues from any such pending applications and any and all divisions, reissues, re-examinations, renewals, continuations, continuations-in-part to the extent the claims are directed to subject matter specifically described in the aforementioned patent application and are dominated by the claims of the existing Patent Rights, and extensions thereof, and all other counterpart, pending or issued patents in all other countries.
Re College OTA # 04-107 Entitled 'Serum Proteomic Methods and Biomarkers for Diagnosis of Neurodegenerative Disease and Differential Diagnosis of Alzheimers, Parkinsons Lou Gehrigs (ALS) Diseases, and other Motor Neuron and Neurological Disorders'
The term Licensed Product(s) shall mean any product, process or service that incorporates, utilizes or is made with the use of the Patent Rights.
IPSCIO Record ID: 308532
Licensor is an institution devoted to diabetes research, care, and education.
The Licensee is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.
IPSCIO Record ID: 342823
CODEX, is an ultra-high parameter and cost-effective platform ideally suited for discovery research with the ability to identify more than 40 biomarkers in a tissue sample.
Biomarkers are objective measures that capture what is happening in a cell or tissue at a given moment. Current genomic and proteomic methods, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry, are providing meaningful data but require the destruction of the tissue sample for analysis.